Table 2.
Open in new tab

Characteristics of PHEO in Relation to Tumor Size ≤4 cm or >4 cm

Variable≤4 cm>4 cmP Value
n130144
Age of diagnosis, y (range)54 (16–81)50 (5–84)0.17
Women, n (%)66 (51.2%)75 (52.5%)0.83
Bilateral disease, n (%)6 (4.6%)16 (11.1%)0.08
Method of discovery, n (%)0.005
 Symptoms28 (21.5%)46 (32.0%)
 Incidental79 (60.8%)89 (61.8%)
 Mutation-based case detection23 (17.7%)9 (6.3%)
Biochemical phenotype, n (%)0.0012
 Adrenergic69 (55.7%)99 (73.4%)
 Noradrenergic43 (34.7%)33 (24.6%)
 Nonfunctioning12 (9.7%)2 (1.5%)
Total plasma metanephrines, nmol/L (range)3.0 (0.4–40)13.9 (0.5–397)<0.0001
 Times greater than ULN3.315.4
Total urinary metanephrines, mcg/24 h (range)1478 (42–8601)6734 (357–128,292)<0.0001
 Times greater than ULN1.15.18
Cumulative dose phenoxybenzamine, mg (range)335 (20–5470)420 (40–4140)0.02
Hospital stay, d (range)2 (1–23)3 (1–32)0.0002
Type of surgery0.0002
 Laparoscopic, n (%)112 (86%)96 (67%)
 Open, n (%)18 (14%)47 (33%)
Variable≤4 cm>4 cmP Value
n130144
Age of diagnosis, y (range)54 (16–81)50 (5–84)0.17
Women, n (%)66 (51.2%)75 (52.5%)0.83
Bilateral disease, n (%)6 (4.6%)16 (11.1%)0.08
Method of discovery, n (%)0.005
 Symptoms28 (21.5%)46 (32.0%)
 Incidental79 (60.8%)89 (61.8%)
 Mutation-based case detection23 (17.7%)9 (6.3%)
Biochemical phenotype, n (%)0.0012
 Adrenergic69 (55.7%)99 (73.4%)
 Noradrenergic43 (34.7%)33 (24.6%)
 Nonfunctioning12 (9.7%)2 (1.5%)
Total plasma metanephrines, nmol/L (range)3.0 (0.4–40)13.9 (0.5–397)<0.0001
 Times greater than ULN3.315.4
Total urinary metanephrines, mcg/24 h (range)1478 (42–8601)6734 (357–128,292)<0.0001
 Times greater than ULN1.15.18
Cumulative dose phenoxybenzamine, mg (range)335 (20–5470)420 (40–4140)0.02
Hospital stay, d (range)2 (1–23)3 (1–32)0.0002
Type of surgery0.0002
 Laparoscopic, n (%)112 (86%)96 (67%)
 Open, n (%)18 (14%)47 (33%)

Abbreviation: ULN, upper limit of normal.

Table 2.
Open in new tab

Characteristics of PHEO in Relation to Tumor Size ≤4 cm or >4 cm

Variable≤4 cm>4 cmP Value
n130144
Age of diagnosis, y (range)54 (16–81)50 (5–84)0.17
Women, n (%)66 (51.2%)75 (52.5%)0.83
Bilateral disease, n (%)6 (4.6%)16 (11.1%)0.08
Method of discovery, n (%)0.005
 Symptoms28 (21.5%)46 (32.0%)
 Incidental79 (60.8%)89 (61.8%)
 Mutation-based case detection23 (17.7%)9 (6.3%)
Biochemical phenotype, n (%)0.0012
 Adrenergic69 (55.7%)99 (73.4%)
 Noradrenergic43 (34.7%)33 (24.6%)
 Nonfunctioning12 (9.7%)2 (1.5%)
Total plasma metanephrines, nmol/L (range)3.0 (0.4–40)13.9 (0.5–397)<0.0001
 Times greater than ULN3.315.4
Total urinary metanephrines, mcg/24 h (range)1478 (42–8601)6734 (357–128,292)<0.0001
 Times greater than ULN1.15.18
Cumulative dose phenoxybenzamine, mg (range)335 (20–5470)420 (40–4140)0.02
Hospital stay, d (range)2 (1–23)3 (1–32)0.0002
Type of surgery0.0002
 Laparoscopic, n (%)112 (86%)96 (67%)
 Open, n (%)18 (14%)47 (33%)
Variable≤4 cm>4 cmP Value
n130144
Age of diagnosis, y (range)54 (16–81)50 (5–84)0.17
Women, n (%)66 (51.2%)75 (52.5%)0.83
Bilateral disease, n (%)6 (4.6%)16 (11.1%)0.08
Method of discovery, n (%)0.005
 Symptoms28 (21.5%)46 (32.0%)
 Incidental79 (60.8%)89 (61.8%)
 Mutation-based case detection23 (17.7%)9 (6.3%)
Biochemical phenotype, n (%)0.0012
 Adrenergic69 (55.7%)99 (73.4%)
 Noradrenergic43 (34.7%)33 (24.6%)
 Nonfunctioning12 (9.7%)2 (1.5%)
Total plasma metanephrines, nmol/L (range)3.0 (0.4–40)13.9 (0.5–397)<0.0001
 Times greater than ULN3.315.4
Total urinary metanephrines, mcg/24 h (range)1478 (42–8601)6734 (357–128,292)<0.0001
 Times greater than ULN1.15.18
Cumulative dose phenoxybenzamine, mg (range)335 (20–5470)420 (40–4140)0.02
Hospital stay, d (range)2 (1–23)3 (1–32)0.0002
Type of surgery0.0002
 Laparoscopic, n (%)112 (86%)96 (67%)
 Open, n (%)18 (14%)47 (33%)

Abbreviation: ULN, upper limit of normal.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close